GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 MARKET SIZE ASSESSMENT
• 2.3 MARKET GROWTH FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 LIMITATIONS
• 2.7 RISK ANALYSIS
• 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 GLP-1 ANALOGUES MARKET OVERVIEW
• 4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
• 4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
• 4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
• 4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032
• 4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Strong R&D pipeline
    • 5.2.1.2 Improved relative efficacy of GLP-1 drugs
    • 5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High barriers for new entrants due to duopoly
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Extended therapeutic uses
    • 5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Off-label use of GLP-1 drugs
    • 5.2.4.2 High non-adherence to therapy after 12-24 months
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
  • 5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
• 5.5 TECHNOLOGY ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
    • 5.5.1.1 Chemical Synthesis
    • 5.5.1.2 Recombinant DNA Technology
  • 5.5.2 ADJACENT TECHNOLOGIES
    • 5.5.2.1 Hydrogel Depot Technology
    • 5.5.2.2 Technologies for oral delivery of GLP-1 analogues
• 5.6 PIPELINE ANALYSIS
• 5.7 TRADE DATA
• 5.8 PATENT ANALYSIS
  • 5.8.1 METHODOLOGY
  • 5.8.2 INNOVATION AND PATENT APPLICATIONS
  • 5.8.3 TOP APPLICANTS
• 5.9 VALUE CHAIN ANALYSIS
• 5.1 SUPPLY CHAIN ANALYSIS
• 5.11 ECOSYSTEM ANALYSIS
  • 5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
  • 5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
  • 5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
  • 5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY SCENARIO
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.14.2.1 North America
    • 5.14.2.2 Europe
    • 5.14.2.3 Asia Pacific
    • 5.14.2.4 Rest of the World
• 5.15 KEY CONFERENCES & EVENTS, 2024-2025
• 5.16 CASE STUDIES
  • 5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
  • 5.16.2 OZEMPIC OFF-LABEL USE
• 5.17 INVESTMENT AND FUNDING SCENARIO

6 GLP-1 ANALOGUES MARKET, BY PRODUCT

• 6.1 INTRODUCTIONS
• 6.2 OZEMPIC
  • 6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH
• 6.3 TRULICITY
  • 6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
• 6.4 MOUNJARO
  • 6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
• 6.5 WEGOVY
  • 6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
• 6.6 RYBELSUS
  • 6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
• 6.7 SAXENDA
  • 6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
• 6.8 VICTOZA
  • 6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
• 6.9 XULTOPHY
  • 6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
• 6.1 SOLIQUA
  • 6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
• 6.11 ZEPBOUND
  • 6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
• 6.12 BYDUREON
  • 6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
• 6.13 OTHER PRODUCTS

7 GLP-1 ANALOGUES MARKET, BY FORMAT

• 7.1 INTRODUCTIONS
• 7.2 SINGLE DOSE
  • 7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
• 7.3 MULTI-DOSE
  • 7.3.1 LOW COST TO ATTRACT LARGER ADOPTION
• 7.4 TABLETS
  • 7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH

8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 INTRODUCTION
• 8.2 SUBCUTANEOUS ADMINISTRATION
  • 8.2.1 PEN INJECTORS
    • 8.2.1.1 Ease of monitoring to support adoption
  • 8.2.2 AUTOINJECTORS
    • 8.2.2.1 Advantages offered over pen injectors to support adoption
• 8.3 ORAL ADMINISTRATION
  • 8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

9 GLP-1 ANALOGUES MARKET, BY INDICATION

• 9.1 INTRODUCTION
• 9.2 DIABETES
  • 9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH
• 9.3 OBESITY
  • 9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
• 9.4 OTHER INDICATIONS

10 GLP-1 ANALOGUES MARKET, BY END USER

• 10.1 INTRODUCTIONS
• 10.2 HOME CARE SETTINGS
  • 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
• 10.4 HOSPITALS & SPECIALTY CLINICS
  • 10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH

11 GLP-1 ANALOGUES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • 11.2.2 US
    • 11.2.2.1 Strategic developments by major players and R&D activities to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Strong research infrastructure and availability of funding to support market growth
• 11.3 EUROPE
  • 11.3.1 EUROPE: RECESSION IMPACT
  • 11.3.2 GERMANY
    • 11.3.2.1 Improving accessibility to support market growth in Germany
  • 11.3.3 UK
    • 11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing awareness to propel market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Favorable initiatives for research to drive market
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 11.4.2 CHINA
    • 11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Access to GLP-1 drugs and government support to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Collaborations in obesity drugs to propel market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to hold largest market share in Latin America
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing diabetes and obesity cases to support market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MIDDLE EAST: RECESSION IMPACT
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth
    • 11.6.2.3 Rest of GCC countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
  • 11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
• 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
  • 12.6.1 STARS
  • 12.6.2 EMERGING LEADERS
  • 12.6.3 PERVASIVE PLAYERS
  • 12.6.4 PARTICIPANTS
  • 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.6.5.1 Company Footprint
    • 12.6.5.2 Format footprint
    • 12.6.5.3 Route of administration footprint
    • 12.6.5.4 Indication footprint
    • 12.6.5.5 Region footprint
• 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.7.1 PROGRESSIVE COMPANIES
  • 12.7.2 RESPONSIVE COMPANIES
  • 12.7.3 DYNAMIC COMPANIES
  • 12.7.4 STARTING BLOCKS
  • 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.8 VALUATION & FINANCIAL METRICS
  • 12.8.1 FINANCIAL METRICS
  • 12.8.2 COMPANY VALUATION
• 12.9 BRAND/PRODUCT COMPARISON
• 12.1 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 INTRODUCTION
• 13.2 KEY PLAYERS
  • 13.2.1 NOVO NORDISK A/S
    • 13.2.1.1 Business overview
    • 13.2.1.2 Products offered
    • 13.2.1.3 Recent developments
      • 13.2.1.3.1 Product approvals
      • 13.2.1.3.2 Expansions
      • 13.2.1.3.3 Other developments
    • 13.2.1.4 MnM view
      • 13.2.1.4.1 Right to win
      • 13.2.1.4.2 Strategic choices
      • 13.2.1.4.3 Weaknesses & competitive threats
  • 13.2.2 ELI LILLY AND COMPANY
    • 13.2.2.1 Business overview
    • 13.2.2.2 Products offered
    • 13.2.2.3 Recent developments
      • 13.2.2.3.1 Product approvals
      • 13.2.2.3.2 Deals
      • 13.2.2.3.3 Expansions
    • 13.2.2.4 MnM view
      • 13.2.2.4.1 Right to win
      • 13.2.2.4.2 Strategic choices
      • 13.2.2.4.3 Weaknesses & competitive threats
  • 13.2.3 SANOFI
    • 13.2.3.1 Business overview
    • 13.2.3.2 Products offered
    • 13.2.3.3 MnM view
      • 13.2.3.3.1 Key strengths
      • 13.2.3.3.2 Strategic choices
      • 13.2.3.3.3 Weaknesses & competitive threats
  • 13.2.4 ASTRAZENECA
    • 13.2.4.1 Business overview
    • 13.2.4.2 Products offered
    • 13.2.4.3 Recent developments
      • 13.2.4.3.1 Product approvals
    • 13.2.4.4 MnM view
      • 13.2.4.4.1 Right to win
      • 13.2.4.4.2 Strategic choices
      • 13.2.4.4.3 Weaknesses & competitive threats
  • 13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    • 13.2.5.1 Business overview
    • 13.2.5.2 Products offered
  • 13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 13.2.6.1 Business overview
    • 13.2.6.2 Products in pipeline
    • 13.2.6.3 Recent developments
      • 13.2.6.3.1 Deals
      • 13.2.6.3.2 Other developments
  • 13.2.7 INNOVENT
    • 13.2.7.1 Business overview
    • 13.2.7.2 Products in pipeline
    • 13.2.7.3 Recent developments
      • 13.2.7.3.1 Other developments
  • 13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
    • 13.2.8.1 Business overview
    • 13.2.8.2 Products in pipeline
  • 13.2.9 SCIWIND BIOSCIENCES CO., LTD.
    • 13.2.9.1 Business overview
    • 13.2.9.2 Products in pipeline
    • 13.2.9.3 Recent developments
      • 13.2.9.3.1 Deals
      • 13.2.9.3.2 Other developments
  • 13.2.10 ZEALAND PHARMA A/S
    • 13.2.10.1 Business overview
    • 13.2.10.2 Products in pipeline
    • 13.2.10.3 Recent developments
      • 13.2.10.3.1 Deals
      • 13.2.10.3.2 Other developments
  • 13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
    • 13.2.11.1 Business overview
    • 13.2.11.2 Products in pipeline
• 13.3 OTHER PLAYERS
  • 13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 13.3.2 VTV THERAPEUTICS
  • 13.3.3 TERNS PHARMACEUTICALS, INC.
  • 13.3.4 ALTIMMUNE
  • 13.3.5 SCOHIA PHARMA, INC.
  • 13.3.6 STRUCTURE THERAPEUTICS
  • 13.3.7 NEUROBO PHARMACEUTICALS, INC.
  • 13.3.8 I2O THERAPEUTICS, INC.
  • 13.3.9 AMGEN INC.
  • 13.3.10 PFIZER INC.
  • 13.3.11 MERCK & CO., INC.
  • 13.3.12 HANMI PHARM CO., LTD.
  • 13.3.13 VIKING THERAPEUTICS
  • 13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
• TABLE 2 GLP-1 ANALOGUES MARKET: IMPACT ANALYSIS
• TABLE 3 AVERAGE SELLING PRICE RANGE OF TOP GLP-1 ANALOGUES (2023–2024)
• TABLE 4 GLP-1 ANALOGUES IN CLINICAL PIPELINE (AS OF MAY 2024)
• TABLE 5 TOP 20 PATENT OWNERS IN GLP-1 ANALOGUES MARKET, 2014–2024
• TABLE 6 INDICATIVE LIST OF PATENTS IN GLP-1 ANALOGUES MARKET, 2022–2024
• TABLE 7 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
• TABLE 8 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
• TABLE 9 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
• TABLE 10 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
• TABLE 11 GLP-1 ANALOGUES MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 12 BUYING CRITERIA FOR GLP-1 ANALOGUES, BY END USER
• TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 17 GLP-1 ANALOGUES MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2024–2025
• TABLE 18 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 19 GLP-1 ANALOGUES MARKET FOR ANTI-OBESITY PRODUCTS (MILLION UNITS)
• TABLE 20 OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 21 NORTH AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 22 EUROPE: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 23 ASIA PACIFIC: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 24 LATIN AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 25 MIDDLE EAST: OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 26 GCC COUNTRIES: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 27 TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 28 NORTH AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 29 EUROPE: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 30 ASIA PACIFIC: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 31 LATIN AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 32 MIDDLE EAST: TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 33 GCC COUNTRIES: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 34 MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 35 NORTH AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 36 EUROPE: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 37 ASIA PACIFIC: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 38 LATIN AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 39 MIDDLE EAST: MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 40 GCC COUNTRIES: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 41 WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 42 NORTH AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 43 EUROPE: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 44 ASIA PACIFIC: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 45 LATIN AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 46 MIDDLE EAST: WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 47 GCC COUNTRIES: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 48 RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 49 NORTH AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 50 EUROPE: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 51 ASIA PACIFIC: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 52 LATIN AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 53 MIDDLE EAST: RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 54 GCC COUNTRIES: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 55 SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 56 NORTH AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 57 EUROPE: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 58 ASIA PACIFIC: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 59 LATIN AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 60 MIDDLE EAST: SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 61 GCC COUNTRIES: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 62 VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 63 NORTH AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 64 EUROPE: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 65 ASIA PACIFIC: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 66 LATIN AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 67 MIDDLE EAST: VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 68 GCC COUNTRIES: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 69 XULTOPHY MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 70 SOLIQUA MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 71 ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 72 NORTH AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 73 EUROPE: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 74 ASIA PACIFIC: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 75 LATIN AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 76 MIDDLE EAST: ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 77 GCC COUNTRIES: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 78 BYDUREON MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 79 OTHER PRODUCTS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 80 GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 81 SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 82 NORTH AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 83 EUROPE: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 84 ASIA PACIFIC: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 85 LATIN AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 86 MIDDLE EAST: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 87 GCC COUNTRIES: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 88 MULTI-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 89 NORTH AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 90 EUROPE: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 91 ASIA PACIFIC: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 92 LATIN AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 93 MIDDLE EAST: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 94 GCC COUNTRIES: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 95 GLP-1 ANALOGUE TABLETS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 96 NORTH AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 97 EUROPE: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 98 ASIA PACIFIC: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 99 LATIN AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 100 MIDDLE EAST: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 101 GCC COUNTRIES: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 102 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 103 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 104 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 105 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
• TABLE 106 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 107 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 108 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 109 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 110 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 111 GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 112 NORTH AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 113 EUROPE: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 114 ASIA PACIFIC: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 115 LATIN AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 116 MIDDLE EAST: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 117 GCC COUNTRIES: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 118 GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 119 NORTH AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 120 EUROPE: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 121 ASIA PACIFIC: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 122 LATIN AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 123 MIDDLE EAST: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 124 GCC COUNTRIES: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 125 ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 126 NORTH AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 127 EUROPE: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 128 ASIA PACIFIC: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 129 LATIN AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 130 MIDDLE EAST: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD MILLION)
• TABLE 131 GCC COUNTRIES: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 132 GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 133 GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
• TABLE 134 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 135 EUROPE: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 136 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 137 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 138 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
• TABLE 139 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 140 GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
• TABLE 141 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 142 EUROPE: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 143 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 144 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 145 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
• TABLE 146 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 147 GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
• TABLE 148 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 149 EUROPE: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 150 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 151 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 152 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
• TABLE 153 GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 154 GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
• TABLE 155 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 156 EUROPE: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 157 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 158 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 159 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
• TABLE 160 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 161 GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
• TABLE 162 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 163 EUROPE: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 164 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 165 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 166 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
• TABLE 167 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 168 GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
• TABLE 169 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 170 EUROPE: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 171 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 172 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 173 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
• TABLE 174 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 175 GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 176 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 177 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 178 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 179 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 180 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 181 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 182 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 183 US: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 184 US: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 185 US: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 186 US: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 187 US: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 188 US: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 189 CANADA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 190 CANADA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 191 CANADA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 192 CANADA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 193 CANADA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 194 CANADA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 195 EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 196 EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 197 EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 198 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 199 EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 200 EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 201 EUROPE: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 202 GERMANY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 203 GERMANY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 204 GERMANY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 205 GERMANY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 206 GERMANY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 207 GERMANY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 208 UK: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 209 UK: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 210 UK: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 211 UK: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 212 UK: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 213 UK: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 214 FRANCE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 215 FRANCE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 216 FRANCE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 217 FRANCE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 218 FRANCE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 219 FRANCE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 220 ITALY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 221 ITALY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 222 ITALY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 223 ITALY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 224 ITALY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 225 ITALY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 226 SPAIN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 227 SPAIN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 228 SPAIN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 229 SPAIN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 230 SPAIN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 231 SPAIN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 232 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 233 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 234 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 235 NETHERLANDS: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 236 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 237 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 238 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 239 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 240 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 241 REST OF EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 242 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 243 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 244 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 245 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 246 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 247 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 248 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 249 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 250 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 251 CHINA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 252 CHINA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 253 CHINA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 254 CHINA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 255 CHINA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 256 CHINA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 257 JAPAN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 258 JAPAN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 259 JAPAN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 260 JAPAN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 261 JAPAN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 262 JAPAN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 263 INDIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 264 INDIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 265 INDIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 266 INDIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 267 INDIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 268 INDIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 269 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 270 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 271 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 272 AUSTRALIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 273 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 274 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 275 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 276 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 277 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 278 SOUTH KOREA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 279 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 280 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 281 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 282 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 283 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 284 REST OF ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 285 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 286 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 287 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 288 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 289 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 290 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 291 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 292 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 293 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 294 BRAZIL: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 295 BRAZIL: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 296 BRAZIL: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 297 BRAZIL: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 298 BRAZIL: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 299 BRAZIL: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 300 MEXICO: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 301 MEXICO: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 302 MEXICO: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 303 MEXICO: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 304 MEXICO: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 305 MEXICO: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 306 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 307 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 308 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 309 REST OF LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 310 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 311 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 312 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 313 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 314 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 315 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 316 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 317 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 318 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
• TABLE 319 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 320 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 321 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 322 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 323 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 324 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 325 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
• TABLE 326 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 327 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 328 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 329 SAUDI ARABIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 330 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 331 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 332 UAE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 333 UAE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 334 UAE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 335 UAE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 336 UAE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 337 UAE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 338 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 339 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 340 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 341 REST OF GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 342 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 343 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 344 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 345 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 346 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 347 REST OF MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 348 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 349 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 350 AFRICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
• TABLE 351 AFRICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
• TABLE 352 AFRICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
• TABLE 353 AFRICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
• TABLE 354 AFRICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
• TABLE 355 AFRICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
• TABLE 356 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
• TABLE 357 GLP-1 ANALOGUES MARKET: DEGREE OF COMPETITION
• TABLE 358 GLP-1 ANALOGUES MARKET: FORMAT FOOTPRINT
• TABLE 359 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
• TABLE 360 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
• TABLE 361 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (KEY PLAYERS)
• TABLE 362 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
• TABLE 363 GLP-1 ANALOGUES MARKET: REGION FOOTPRINT (KEY PLAYERS)
• TABLE 364 GLP-1 ANALOGUES MARKET: DETAILED LIST OF KEY START-UPS/SMES
• TABLE 365 GLP-1 ANALOGUES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 366 GLP-1 ANALOGUES MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
• TABLE 367 GLP-1 ANALOGUES MARKET: DEALS, JANUARY 2021–MAY 2024
• TABLE 368 GLP-1 ANALOGUES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024
• TABLE 369 GLP-1 ANALOGUES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
• TABLE 370 NOVO NORDISK A/S: COMPANY OVERVIEW
• TABLE 371 NOVO NORDISK A/S: PRODUCTS OFFERED
• TABLE 372 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
• TABLE 373 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–APRIL 2024
• TABLE 374 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
• TABLE 375 ELI LILLY AND COMPANY: COMPANY OVERVIEW
• TABLE 376 ELI LILLY AND COMPANY: PRODUCTS OFFERED
• TABLE 377 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
• TABLE 378 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–APRIL 2024
• TABLE 379 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–APRIL 2024
• TABLE 380 SANOFI: COMPANY OVERVIEW
• TABLE 381 SANOFI: PRODUCTS OFFERED
• TABLE 382 ASTRAZENECA: COMPANY OVERVIEW
• TABLE 383 ASTRAZENECA: PRODUCTS OFFERED
• TABLE 384 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
• TABLE 385 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
• TABLE 386 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
• TABLE 387 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
• TABLE 388 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS IN PIPELINE
• TABLE 389 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–APRIL 2024
• TABLE 390 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
• TABLE 391 INNOVENT: COMPANY OVERVIEW
• TABLE 392 INNOVENT: PRODUCTS IN PIPELINE
• TABLE 393 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
• TABLE 394 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: COMPANY OVERVIEW
• TABLE 395 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: PRODUCTS IN PIPELINE
• TABLE 396 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW
• TABLE 397 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS IN PIPELINE
• TABLE 398 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2021–APRIL 2024
• TABLE 399 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
• TABLE 400 ZEALAND PHARMA A/S: COMPANY OVERVIEW
• TABLE 401 ZEALAND PHARMA A/S: PRODUCTS IN PIPELINE
• TABLE 402 ZEALAND PHARMA A/S: DEALS, JANUARY 2021–APRIL 2024
• TABLE 403 ZEALAND PHARMA A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
• TABLE 404 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: COMPANY OVERVIEW
• TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE
• TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE

List of Figures

• FIGURE 1 GLP-1 ANALOGUES MARKET SEGMENTATION
• FIGURE 2 GLP-1 ANALOGUES MARKET: REGIONAL SEGMENTATION
• FIGURE 3 RESEARCH DESIGN
• FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
• FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
• FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
• FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
• FIGURE 8 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
• FIGURE 9 CAGR PROJECTIONS: GLP-1 ANALOGUES MARKET, 2024–2032
• FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 ANALOGUES MARKET
• FIGURE 11 DATA TRIANGULATION METHODOLOGY
• FIGURE 12 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2024 VS. 2032 (USD BILLION)
• FIGURE 13 GLP-1 ANALOGUES MARKET SHARE, BY FORMAT, 2024 VS. 2032 (USD BILLION)
• FIGURE 14 GLP-1 ANALOGUES MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD BILLION)
• FIGURE 15 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2024 VS. 2032 (USD BILLION)
• FIGURE 16 GLP-1 ANALOGUES MARKET, BY END USER, 2024-2032 (USD BILLION)
• FIGURE 17 GLP-1 ANALOGUES MARKET: GEOGRAPHICAL SNAPSHOT
• FIGURE 18 IMPROVED EFFICACY OF GLP-1 DRUGS TO DRIVE MARKET GROWTH
• FIGURE 19 DIABETES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
• FIGURE 20 OZEMPIC TO DOMINATE MARKET IN 2032
• FIGURE 21 DIABETES INDICATIONS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
• FIGURE 22 HOME CARE SETTINGS TO DOMINATE THE MARKET IN 2032
• FIGURE 23 US TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 24 GLP-1 ANALOGUES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 25 US: PREVALENCE OF INDICATIONS THAT MAY RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)
• FIGURE 26 REVENUE SHIFT IN GLP-1 ANALOGUES MARKET
• FIGURE 27 AVERAGE SELLING PRICE TREND, BY PRODUCT
• FIGURE 28 PRODUCT PRICING, BY COUNTRY (2023–2024)
• FIGURE 29 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2025–2032
• FIGURE 30 PHASE 3 PIPELINE, BY INDICATION
• FIGURE 31 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
• FIGURE 32 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
• FIGURE 33 VALUE CHAIN ANALYSIS: PRODUCT DEVELOPMENT AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
• FIGURE 34 GLP-1 ANALOGUES MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 35 GLP-1 ANALOGUES MARKET: ECOSYSTEM ANALYSIS
• FIGURE 36 GLP-1 ANALOGUES MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 ANALOGUES, HOSPITALS
• FIGURE 38 KEY BUYING CRITERIA FOR END USERS
• FIGURE 39 NORTH AMERICA GLP-1 ANALOGUES MARKET SNAPSHOT
• FIGURE 40 EUROPE: GLP-1 ANALOGUES MARKET SNAPSHOT
• FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2021–2023
• FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2023
• FIGURE 43 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 44 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
• FIGURE 45 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
• FIGURE 46 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
• FIGURE 47 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 48 EV/EBITDA OF KEY VENDORS
• FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 50 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTIDIABETIC GLP-1 ANALOGUES)
• FIGURE 51 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTI-OBESITY GLP-1 ANALOGUES)
• FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT
• FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
• FIGURE 54 SANOFI: COMPANY SNAPSHOT
• FIGURE 55 ASTRAZENECA: COMPANY SNAPSHOT
• FIGURE 56 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT
• FIGURE 57 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
• FIGURE 58 INNOVENT: COMPANY SNAPSHOT
• FIGURE 59 ZEALAND PHARMA A/S: COMPANY SNAPSHOT